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Aim To assess whether the simultaneous performance of 
exercise stress echocardiography and cardio-pulmonary 
testing (ESE-CPET) may facilitate the timely diagnosis of 
subclinical left ventricular diastolic dysfunction (LVDD) in 
patients with non-severe chronic obstructive pulmonary 
disease (COPD), preserved left ventricular systolic function, 
and exertional dyspnea or exercise intolerance.
Methods This cross-sectional study, conducted between 
May 2017 and April 2018, involved 104 non-severe COPD 
patients with exertional dyspnea and preserved ejection 
fraction who underwent echocardiography before CPET 
and 1-2 minutes after peak exercise. Based on the peak 
E/e’ ratio, patients were divided into the group with stress-
induced LVDD – E/e’>15 and the group without stress-in-
duced LVDD. We assessed the association between LVDD 
and the following CPET variables: minute ventilation, peak 
oxygen uptake (VO2), ventilatory efficiency, heart rate re-
serve, and blood pressure.
Results During ESE-CPET, stress-induced LVDD occurred 
in 67/104 patients (64%). These patients had lower work 
load, peak VO2, O2 pulse, and minute ventilation (VE), and 
higher VE/VCO2 slope than patients without stress-induced 
LVDD (35.18 ± 10.4 vs 37.01 ± 11.11, P < 0.05). None of the 
CPET variables correlated with E/e’.
Conclusion Combined ESE-CPET may distinguish masked 
LVDD in patients with non-severe COPD with exertional 
dyspnea and preserved left ventricular systolic function. 
None of the CPET variables was a predictor for subclinical 
LVDD.
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During the last decade, chronic obstructive pulmonary dis-
ease (COPD) has caused significant morbidity and mortal-
ity (1). COPD patients have greater than 2-fold excess risk of 
cardiovascular events and greater than 4-fold risk of devel-
oping chronic heart failure or coronary artery disease (2,3). 
Even patients with mild COPD have sub-clinical functional 
and structural changes, which, as airway obstruction grad-
ually progresses, evolve to an overt disease (4). Therefore, 
an early detection and proper risk assessment are impor-
tant for the control and prevention of cardiovascular co-
morbidities in COPD.
Studies using magnetic resonance imaging established 
that patients with mild COPD without diseases, hyperten-
sion, or diabetes have arterial stiffness and myocardial fi-
brosis (5-8). Both pathologies are manifestations of the 
systemic effects of COPD and are a precondition for left 
ventricular diastolic dysfunction (LVDD) (9,10). In addition, 
chest wall hyperinflation and intra-thoracic pressure gra-
dients may influence left ventricular (LV) pre-load and/or 
afterload (11). Thus, systemic and hemodynamic effects 
associated with the pathophysiological abnormalities of 
COPD are preconditions for LVDD.
Dyspnea and exercise intolerance are common symptoms of 
both COPD and heart failure with preserved ejection fraction 
(12,13). This is why there is need for cardio-respiratory param-
eters that discriminate between cardiac and respiratory na-
ture of dyspnea or diminished physical activity (14,15).
There are no studies dealing with the problem of masked 
heart failure in COPD population. We hypothesized that 
the simultaneous performance of exercise stress echocar-
diography and cardio-pulmonary testing (ESE-CPX) may 
facilitate the timely diagnosis of subclinical LVDD in pa-
tients with non-severe COPD, preserved left ventricular 
systolic function (LVSF), and exertional dyspnea or exercise 
intolerance. The aims of the current study are to detect the 
frequency of exercise-induced LVDD in non-severe, non-
symptomatic at rest COPD patients and to establish CPET 
parameters that can be applied as surrogate markers for 
masked LVDD.
MatERialS anD MEthoDS
Patients and study protocol
This cross-sectional study involved 224 clinically stable 
outpatients diagnosed with COPD at the University 
Hospital for Respiratory Diseases “St. Sophia” in So-
fia, Bulgaria. Only 163 of them met the inclusion criteria 
– FEO1 > 50% and lack of overt cardiovascular diseases. All 
patients had exertional dyspnea and preserved left ven-
tricular systolic function. The following exclusion criteria 
were used: 1) LVEF<50%; 2) LVDD at rest more than first 
grade; 3) echocardiographic signs of systolic pulmonary ar-
terial hypertension; 4) valvular heart disease; 5) document-
ed cardiomyopathy; 6) severe uncontrolled hypertension 
(systolic blood pressure >180 mm Hg and diastolic blood 
pressure >90 mm Hg); 7) atrial fibrillation or malignant ven-
tricular arrhythmia; 8) anemia; 9) cancer; 10) chronic kidney 
disease; 11) recent chest or abdominal surgery; 12) recent 
exacerbation (during the last three months); 13) recent 
change (during the last three months) in medical thera-
py. Based on these criteria, 59 patients were excluded, and 
104 patients (64 men; mean age of 62.9 ± 7.5 years) were 
considered eligible (Figure 1). The recruitment period last-
ed between May 2017 and April 2018. The study was ap-
proved by the Committee of Ethics of Science Research, 
Medical University Sofia (protocol 5/12.03.2018). All the pa-
tients signed informed consent before entering the study.
Patients’ data included general demographic information, 
self-reported medical history, and concomitant medication. 
Demographic and clinical data are presented in Table 1.
Pulmonary function testing
All participants underwent preliminary clinical examination 
that included chest x-ray, spirometry, electrocardiogram, 
and echocardiography. The patients eligible for the study 
performed spirometry and exercise stress test. Both tests 
were performed on Vyntus (Carefusion, Baesweiler, Germa-
ny) following the manufacturer’s instructions. Spirometry 
was performed after bronchodilation test with the applica-
tion of 400 mg salbutamol. Following the ERS guidelines, a 
post-bronchodilation ratio of FEV1/FVC<70% was used as a 
diagnostic criterion of COPD (16). Only patients with mild/
moderate airway obstruction (FEV1 > 50%) were selected.
Six-minute walk test
Six-minute walk test was performed in accordance with 
the ATS guidelines (17). It was done on a separate day after 
the initial visit and after the exercise stress test and stress 
echocardiography. Participants were instructed to walk the 
previously measured 30-m distance in a hospital corridor. 
SpO
2, heart rate, and arterial blood pressure were obtained 
before and during the recovery period, 1 minute after the 
end of the test.
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Stress test protocol – cardio-pulmonary exercise testing 
(CPEt)
After the clinical examination and spirometry, all the pa-
tients underwent symptom-limited incremental exercise 
stress test on a supine bicycle in accordance with the 
guidelines (18). Gas and flow sensors were calibrated be-
fore each test. Patients underwent standard electrocar-
diography through the whole exercise test and manual 
blood pressure measurements and heart rate recordings 
at the end of every stage.
A continuous RAMP protocol was applied – two minutes 
of unloaded pedaling (rest phase – 0W), a three-minute 
warm-up phase (20W), and the test phase including 20 
W/2-min load increments. Patients were instructed to ped-
al with 60 rotations per minute.
Expiratory gases were analyzed by breath-by-breath anal-
ysis. Peak values of oxygen consumption, carbon dioxide 
production, and ventilatory efficiency (VE/VCO2) are pre-
sented as the highest 30-second average value obtained 
during the last stage of the exercise test. These values were 
used to estimate peak respiratory exchange ratio (RER). 
RER>1.00 was considered as a maximum effort. The modi-
fied Borg scale was applied for peak dyspnea evaluation. 
Heart rate recovery was defined as the difference between 
peak heart rate and heart rate during the first minute of 
recovery.
Electrocardiography
Twelve-lead electrocardiography was performed during 
the four phases of the cardio-pulmonary test. The test 
was terminated because of exertion – exercise-limiting 
dyspnea, fatigue, claudication, or severe chest pain at pa-
tient’s request or because of clinical indications – emer-
gence of repolarization ST-T changes, decrease in systolic 
blood pressure of more than 20 mm Hg, increase in systol-
ic blood pressure of more than 220 mm Hg, or malignant 
arrhythmias.
Echocardiography methods
Echocardiography included the generally applied ap-
proaches of M-mode and two-dimensional and 
FiGuRE 1. Study flowchart. FVC – forced vital capacity; FEV1 – forced expiratory volume 1; lVEF – left ventricular systolic function; 
lVDD left ventricular diastolic dysfunction.
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Doppler echocardiography. Routine structural and hemo-
dynamic indices of both chambers were measured follow-
ing the guidelines (19). The systolic function of the left ven-
tricle was defined by Simpson’s modified rule. The diastolic 
function of both ventricles was evaluated by the E/A ratio 
at rest (20) and tissue Doppler analysis as a more precise 
approach. The e’ value was defined as the average of the 
medial and lateral measurements of the mitral annulus. 
The peak of the average E/e’ ratio greater than 15 was con-
sidered as a marker for stress induced LVDD.
The dimensions of the right ventricle were assessed 
from the long-axis parasternal and apical four chamber 
view (21). TAPSE and S peak velocity were analyzed for 
RV systolic function evaluation. RVWT was measured in 
end-diastole. Systolic pulmonary arterial pressure was 
calculated by Bernoulli equation and by the accelera-
tion time (AT) (22,23). Right atrium volume index (RAVI) 
was measured at end-systole by Simpson’s modified 
rule. Reference range for RAVI averages 25 ± 7 mL/
m2 in men and 21 ± 6 mL/m2 in women. Stress in-
duced RV diastolic dysfunction was considered if stress 
induced E/e’ ratio was higher than 6. All parameters 
were measured at end-expiration and in triplicate dur-
ing different heart cycles.
Statistical analysis
Descriptive statistics was used to summarize demographic 
and clinical data. Normality of distribution was tested with 
the Kolmogorov-Smirnov test. Continuous variables are 
expressed as mean values ± standard deviation, while cat-
egorical variables are expressed as proportions. Normally 
distributed variables were compared between the patients 
with and without LVDD with the t test, whereas non-nor-
mally variables were compared with the Mann-Whitney-U 
test. Categorical variables were compared with the χ2 test 
or Fisher exact test. The correlation between CPET param-
eters and the presence of LVDD was assessed by the Spear-
man’s rank correlation test. The level of significance was set 
at P < 0.05. The analyses were conducted in SPSS, v. 13.0 
(SPSS Inc. Chicago, IL, USA).
taBlE 1. Clinical and demographic characteristics of patients with and without left ventricular diastolic dysfunction (lVDD)
number (%) of patients
Demographic data
without stress -induced 
lVDD (n = 37)
with stress -induced lVDD 
(n = 67) P
age (years), mean ± standard deviation  60.44 ± 7.72  64.16 ± 6.97 0.143*
Male, n  21:16  44:23 0.298‡
Current smokers  23 (62)  39 (58) 0.176‡
Former smokers   4 (11)  17 (25) 0.981‡
non-smokers  10 (27)  11 (17) 0.375‡
Pack years, mean ± standard deviation  27.21 ± 6.33  33.79 ± 3.04 0.491‡
Body mass index (kg/m2), mean ± standard deviation  27.38 ± 4.58  26.65 ± 6.7 0.207†
Clinical data
systolic blood pressure (mmHg), mean ± standard deviation 128.16 ± 9.68 128.17 ± 11.39 0.217†
diastolic blood pressure (mmHg), mean ± standard deviation  81.11 ± 5.54  82.31 ± 6.53 0.206†
Discharge medication
inhaled β2 agonists  26(70)  67(100) 0.721‡
inhaled anticholinergic medications  17 (46)  38(57) 0.409‡
inhaled corticosteroids  18 (48)  50 (75) 0.031‡
angiotensin converting enzyme Inhibitors  22 (59)  54 (81) 0.026‡
β blockers   7 (19)  22 (33) 0.027‡
diuretics  25 (67)  52 (78) 0.043‡
Medical history
diabetes   6 (16)  13 (19) 0.721‡
systemic hypertension  23 (62)  54 (81) 0.483‡
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RESultS
Participants had a mean age of 62.9 ± 7.5 years and body 
mass index of 27.02 ± 6.3 kg/m2. According to the stress 
echocardiography results, they were divided into the group 
with stress-induced LVDD and the group without stress-in-
duced LVDD. The groups did not differ in anthropometric, 
respiratory (Table 2), or other clinical characteristics. After 
ESE-CPX, 64% (67/104) of patients showed stress-induced 
LVDD (E/e’>15). Other LV and RV structural and functional 
parameters are shown in Table 3. Patients with stress-in-
duced LVDD had a significant increase in systolic pulmo-
nary arterial pressure (baseline 27.92 ± 2.97 mmHg vs stress 
induced 38.80 ± 3.83 mmHg, P < 0.0001) (Table 3). Non-se-
vere COPD patients with stress-induced LVDD compared 
with non-severe COPD patients without stress-induced 
LVDD showed limited exercise capacity (Table 4), achieving 
lower load, VO2, and O2-pulse. They performed with signifi-
cantly higher VE/VCO2 slope (35.18 ± 10.4 vs 37.01 ± 11.11, 
P = 0.032; Table 4). None of the CPET parameters correlated 
with stress induced LVDD.
DiSCuSSion
This study found 1) a high frequency (64%) of stress-in-
duced LVDD in non-severe COPD patients with exertion-
al dyspnea and preserved LV ejection fraction; 2) stress-
induced elevation of systolic pulmonary arterial pressure 
(>35 mm Hg) and a reduced functional capacity, as mea-
sured by both CPET and 6-min walk, in participants with 
stress-induced LVDD; 3) difference in CPET variables be-
tween patients with and without stress-induced LVDD, but 
no correlation of these variable to stress E/e’. These results 
only partially confirm our hypothesis, as we expected that 
in addition to the high prevalence of stress-induced LVDD, 
some CPET parameters would predict LVDD. The reasons 
for the discrepancy may be the complex lung-heart inter-
action during exercise and multifactorial nature of LVDD.
COPD is a multi-systemic disease that remains a worldwide 
leading cause of disability (24,25). Compared with the gen-
eral population, COPD patients bear a two to 5-fold in-
creased risk of cardiovascular complications, with cardio-
vascular morbidity as the cause of death in a third of these 
patients (26). COPD is an independent predictor for vascu-
lar damage (27,28) and is associated with increased arte-
rial stiffness and myocardial fibrosis, which may be present 
in COPD patients free of manifest cardiovascular diseases 
(11,28-32). Both pathological abnormalities are a precon-
dition for a higher prevalence of LVDD in COPD patients 
(6,13). The link between LVDD and COPD is complex and 
is probably a result of various mechanisms – mechani-
cal/functional (deterioration in FEV1, emphysema, hyper-
inflation) (5,11,33-35), biological (systemic inflammation, 
hypoxemia, endothelial dysfunction) (36-38), and neuro-
humoral (excess sympathetic nerve activity) (39). Each of 
these may be a trigger in a certain phenotype of COPD pa-
tients (40-42).
Cardio-respiratory parameters may discriminate between 
the cardiac and respiratory nature of dyspnea/diminished 
physical activity and facilitate the early diagnosis of cardio-
vascular pathology in COPD. Our results, however, show 
that none of these parameters correlated with stress in-
duced LVDD (E/e’>15). These results differ from data ob-
tained in the general population, which had a significantly 
taBlE 2. Respiratory parameters of patients with and without left ventricular diastolic dysfunction (lVDD)*
Parameter, mean ± standard deviation
Patients without stress-induced lVDD 
(n = 37)
Patients with stress-induced lVDD 
(n = 67) P†
Respiratory function
FVC, l/min  2.60 ± 0.93  2.38 ± 0.74 0.213
FEV 1, l/min  1.71 ± 0.66  1.47 ± 0.42 0.408
FEV1/FVC % 62.12 ± 9.46 53.87 ± 14.39 0.764
mMRC  1.55 ± 0.49  1.70 ± 0.79 0.891
acid-base balance
pH  7.44 ± 0.03  7.43 ± 0.03 0.329
O2, mmHg 68.09 ± 10.44 67.48 ± 10.19 0.298
CO2, mmHg 35.96 ± 9.49 37.14 ± 8.03 0.275
BE, mmol/L  3.80 ± 5.63  2.39 ± 1.79 0.872
HCO3
-, mmol/L 21.73 ± 6.46 24.28 ± 3.48 0.328
Saturation % 94.15 ± 2.00 94.01 ± 2.27 0.763
*FVC – forced vital capacity; FEV1 – forced expiratory volume 1; mMRC – modified Medical Research Council; BE – base excess.
†Mann-Whitney u test.
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lower prevalence of exercise-induced LVDD. Nedeljkovic et 
al (43) performed ESE in 87 patients with exertional dys-
pnea, hypertension, and normal left ventricular function, 
9.2% of whom demonstrated E/e’>15. In the study by Ta-
lal et al (44), among 87 patients with exertional dyspnea, 
9% had E/A<0.75. Guazzi et al (45) reported an association 
between diastolic dysfunction (E/e’ ratio) and peak oxygen 
consumption, ventilatory efficiency, and heart rate recov-
ery. In patients with normal echocardiography at rest, peak 
E/e’ ratio >15 correlated best to ventilatory efficiency (43). 
VE/VCO2 ratio as the best predictor of stress E/e’ was also 
confirmed in a diastolic heart failure group (45).
Since LVDD is associated with an increased risk of exacer-
bations and mortality, its timely diagnosis in non-severe 
COPD is important for disease management. As none of 
the clinical, ventilatory, cardio-pulmonary, and echocardio-
graphic characteristics can predict stress-induced LVDD in 
taBlE 3. Echocardiographic characteristics of patients with and without left ventricular diastolic dysfunction (lVDD)*
Parameter, mean ± standard deviation
Patients without stress-induced lVDD 
(n = 37)
Patients with stress-induced lVDD 
(n = 67) P†
lV structural parameters
LVEF, %, Teicholz  62.69 ± 4.02  62.09 ± 6.34   0.653
LVEF, %, Simpson  63.05 ± 3.80  60.40 ± 6.44   0.016
TDD, mm  52.22 ± 5.16  50.98 ± 4.61   0.253
TSD, mm  33.94 ± 4.37  33.48 ± 4.72   0.275
TDV, mL 131.88 ± 30.18 122.44 ± 25.19   0.181
TSV, mL  49.63 ± 14.85  46.80 ± 16.32   0.187
Septum, mm  12.01 ± 1.01  12.00 ± 1.19   0.897
PW, mm  12.05 ± 0.94  12.03 ± 1.14   0.981
lV functional parameters at rest
E/A ratio   0.94 ± 0.70   0.98 ± 0.32   0.420
E’ average, cm/s   8.36 ± 1.47   9.62 ± 1.69   0.003
E/e’ average ratio   7.30 ± 1.89   7.12 ± 2.59   0.736
lV functional parameters after exercise stress test
E/A ratio   0.92 ± 0.68   1.79 ± 0.42 <0.0001
E’ average, cm/s  10.55 ± 2.24   6.78 ± 0.90 <0.0001
E/e’ average   9.04 ± 1.89  17.18 ± 3.17 <0.0001
RV structural parameters
RAVI, mL/m2  18.29 ± 2.65  23.04 ± 2.65 <0.0001
RVWT, mm   5.41 ± 1.08   6.53 ± 0.53 <0.0001
RV diameter parasternal, mm  28.02 ± 2.83  28.25 ± 2.25   0.687
RV basal, mm  36.30 ± 2.97  37.12 ± 3.25   0.095
RV med, mm  24.01 ± 3.43  27.24 ± 2.06 <0.0001
RV functional parameters at rest
E/A ratio   0.92 ± 0.31   0.67 ± 0.14 <0.0001
E/e’ average   4.72 ± 1.42   4.64 ± 1.01   0.064
TAPSE, mm  23.86 ± 2.82  22.39 ± 1.82   0.009
AT, ms 170.39 ± 12.08 169.59 ± 12.14   0.737  
sPAP, mmHg  26.80 ± 2.42  27.92 ± 2.97   0.092
RV functional parameters after exercise stress test
E/A ratio   1.39 ± 0.27   1.37 ± 0.21   0.830
E/e’ average   4.82 ± 1.6   9.60 ± 2.74 <0.0001
TAPSE, mm  21.25 ± 0.95  21.34 ± 1.85   0.324
AT, ms 163.33 ± 15.99 103.62 ± 16.04 <0.0001
sPAP, mmHg  31.86 ± 2.17  38.80 ± 3.83 <0.0001
*lVEF – left ventricular ejection fraction; tDD – telediastolic diameter; tSD – telesystolic diameter; tDV – tissue Doppler velocity; tSV – total stroke 
volume; PW – posterior wall thickness at end-diastole; RV – right ventricle; RaVi – right atrium volume index; RVWt – right ventricular wall thickness; 
taPSE – tricuspid annular plane systolic excursion; SPaP –systolic pulmonary arterial pressure.
†Mann-Whitney u test.
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non-severe COPD, the combined ESE can facilitate its early 
diagnosis.
Our study has the following limitations: 1) the relatively 
small sample size; 2) the lack of body plethysmography for 
the measurement of hyperinflation and the lack of diffu-
sion capacity measurements, which are informative for the 
proper assessment of dyspnea; 3) measurements were per-
formed at the end of expiration due to the huge pressure 
gradients accompanying the respiratory cycle in COPD pa-
tients; 4) measurements were performed in the early re-
covery period (approximately 2 min) after symptom-lim-
ited exercise. The timeline of pulmonary and intrathoracic 
pressures changes during the brief time interval from peak 
exercise to their measurement in early recovery is not well 
known, leading to possible underestimation.
In non-severe COPD patients with preserved LV systolic 
function, the combined ESE-CPX test can reliably identify 
stress-induced LVDD, the early diagnosis and proper man-
agement of which may facilitate the prevention of cardio-
vascular complications. Although none of the routine clini-
cal and CPET parameters predicted increased E/e’, the high 
prevalence of exercise-induced LVDD in these patients in-
dicates the need for performing stress echocardiography. 
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